Latest Market Report | PD L1 Biomarker Testing Market Analysis, Industry Trends, Growth Opportunities and Forecast, 2023-2030

The global PD L1 biomarker testing market is expected to touch US$ 14.2 billion by 2030, with an annual growth rate of more than 16.5% says RationalStat


Wilmington, Delaware, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Global PD L1 Biomarker Testing Market is valued at US$ 4.9 billion in 2023 and is expected to grow at a significant CAGR of over 16.5% over the forecast period of 2023-2030, according to the published market report by RationalStat


Market Definition, Market Scope, and Report Overview

Programmed Death-Ligand 1 (PD-L1) biomarker testing is a diagnostic procedure used in the field of oncology to assess the expression of PD-L1 proteins in tumor cells. PD-L1 is a protein that can be found on the surface of certain cancer cells and other immune cells. This biomarker testing is primarily used to help determine the potential effectiveness of immune checkpoint inhibitors, a type of cancer immunotherapy.

The global burden of cancer continues to increase, leading to a growing demand for more effective and targeted cancer treatments. PD-L1 biomarker testing helps identify patients who may benefit from immunotherapies, which are becoming a standard part of cancer treatment.

  • According to a deep-dive market assessment by RationalStat, the global PD L1 biomarker testing market has been analyzed on the basis of market segments, including product type, end user and geography/regions (including North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa, and Asia Pacific). The report also offers global and regional market sizing for the historical period of 2019-2022 and the forecast period of 2023-2030.
  • Market intelligence for the global PD L1 biomarker testing market covers market sizes on the basis of market value (US$/EUR Million) and volume (Units) by various products/services/equipment, demand assessment across the key regions, customer sentiments, price points, cost structures, margin analysis across the value chain, financial assessments, historical and forecast data, key developments across the industry, import-export data, trade overview, components market by leading companies, etc.
  • In addition, the long-term sector and products/services 10-year outlook and its implications on the global PD L1 biomarker testing market. It also includes the industry's current state – Production Levels, Capacity Utilization, Tech quotient, etc. Key information will be manufacturing capacity by country, installed base, import volumes, market size, key players, market size, dynamics, market data, insights, etc.

Request A Customization- https://store.rationalstat.com/store/global-pd-l1-biomarker-testing-market/#tab-ux_global_tab

Global PD L1 Biomarker Testing Market: Segmental and Market Share Analysis

  • On the basis of end users, research institutes is expected to dominate the PD L1 biomarker testing market.

Report Synopsis

Report Metrics Details
Base Year 2023
Forecast Period 2023-2030
Base Year Market Size US$ 4.9 billion
Market Size Forecast US$ 14.2 billion
Growth Rate 16.5%
Key Market Drivers
  • Rising incidence of cancer
  • Emerging cancer types
  • Rising awareness amongst patients
Companies Profiled
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Thermo Fisher Scientific
  • Agilent
  • Abbott Laboratories
  • Leica Biosystems
  • Bio-Rad Laboratories
  • Genentech

Explore more about this report- https://store.rationalstat.com/store/global-pd-l1-biomarker-testing-market/#tab-ux_global_tab

Competition Analysis and Market Structure

These players adopt various strategies in order to reinforce their market share and gain a competitive edge over other competitors in the market. Mergers & acquisitions, partnerships and collaborations, and product launches are some of the strategies followed by industry players. Some of the key developments in the global PD L1 biomarker testing market include,

  • In March 2023, Roche received approval from FDA for its VENTANA PD- L1 (SP263) Assay designed to identify patients with locally advanced and metastatic non-small cell lung cancer.

Some of the prominent players and suppliers operating and contributing significantly to the global PD L1 biomarker testing market growth include Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Thermo Fisher Scientific, Agilent, Abbott Laboratories, Leica Biosystems, Bio-Rad Laboratories, and Genentech, among others.

Get A Free Sample- https://store.rationalstat.com/store/global-pd-l1-biomarker-testing-market/#tab-ux_global_tab

RationalStat has segmented the global PD L1 biomarker testing market based on product type, end user and region

  • Global PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Product Type
    • PD-L1 22C3 Assay Kit
    • PD-L1 28-8 Assay Kit
    • PD-L1 SP142 Assay Kit
    • PD-L1 263 Assay Kit
  • Global PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by End User
    • Research
    • Diagnostic Laboratories
    • Hospitals
    • Others
  • Global PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Region
    • North America PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • US
      • Canada
    • Latin America PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • Brazil
      • Mexico
      • Rest of Latin America
    • Western Europe PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • Russia
      • Poland
      • Hungary
      • Other CIS Countries
      • Rest of Eastern Europe
    • Asia Pacific PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • ASEAN
        • Indonesia
        • Thailand
        • Philippines
        • Vietnam
        • Malaysia
        • Rest of ASEAN
      • Rest of Asia Pacific
    • Middle East & Africa PD L1 Biomarker Testing Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Country
      • GCC
        • Saudi Arabia (KSA)
        • United Arab Emirates (UAE)
        • Rest of the GCC
      • South Africa
      • Nigeria
      • Turkey
      • Rest of the Middle East & Africa

For more information about this report- https://store.rationalstat.com/store/global-pd-l1-biomarker-testing-market/

Key Questions Answered in the PD L1 Biomarker Testing Report:

  • What will be the market value of the global PD L1 biomarker testing market by 2030?
  • What is the market size of the global PD L1 biomarker testing market?
  • What are the market drivers of the global PD L1 biomarker testing market?
  • What are the key trends in the global PD L1 biomarker testing market?
  • Which is the leading region in the global PD L1 biomarker testing market?
  • What are the major companies operating in the global PD L1 biomarker testing market?
  • What are the market shares by key segments in the global PD L1 biomarker testing market?  

Running a year End discount of 20%-https://store.rationalstat.com/store/global-pd-l1-biomarker-testing-market/#tab-ux_global_tab

Explore Our Trending Reports

Research Methodology

RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.

RationalStat combines a mix of secondary sources as well as primary research to assess the market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:

  • Defining the problem by understanding the type of market and data required by the client.
  • Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
  • Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
  • Evaluating and analyzing the data by referring to data sources utilized and leveraged.
  • Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.

Download Key Insights and Market Data - Raise a Query

About RationalStat LLC                    

RationalStat is an end-to-end global market intelligence and consulting company that provides comprehensive market research reports, customized strategy, and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.

RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, valuations and advisory, financial research, due diligence, procurement and supply chain research, data analytics, and analytical dashboards.

Contact

RationalStat LLC

Kimberly Shaw,

Content and Press Manager

sales@rationalstat.com

US Phone: +1 302 803 5429

UK Phone:  +44 203-287-1245

LinkedIn | FacebookTwitterInstagramPinterest